The deal is mainly focused on Incyte’s investigational mutant calreticulin selective monoclonal antibody treatment for the blood disorder essential thrombocythemia and the chronic bone marrow disorder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback